Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
Takeda Pharmaceutical Company Limited China (TYO: 4502; NYSE: TAK) entered into a partnership agreement with...
EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk
Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for...
Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has signed an exclusive licensing...
GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027
GlaxoSmithKline Plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has...
Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
The U.S. Court of Appeals for the Third Circuit ruled against Merck & Co., Inc....
WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
WuXi XDC (HKG: 2268) reported interim results for the first half of 2026 on Aug....
China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
China’s National Health Commission (NHC), together with the National Administration of Traditional Chinese Medicine and...
Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
Mirxes Holding Company Limited (HKG: 2629) announced that its clinical diagnostic laboratory, M Diagnostics Philippines...
Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China’s National Medical Products...
Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
Antengene Corporation Limited (HKG: 6996) announced that the Phase I ATTRACT study of its proprietary...
InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of...
NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
China’s National Medical Products Administration (NMPA) issued the Catalog of Reference Listed Drugs for Generic...
Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug...
Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced that its Category 1 chemical drug APH03867 Tablets...
ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
ImmuneOnco Biopharmaceuticals (HKG: 1541) announced that its drug IMM0306 has received Investigational New Drug (IND)...
North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
North China Pharmaceutical Co., Ltd. (SHA: 600812) announced that its hexavalent recombinant norovirus vaccine (Hansenula...
Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting...
Hengrui Pharma Wins NMPA Approval for Three Clinical Trials Led by First‑in‑Class SHR‑7012 for Cutaneous Lupus
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that three investigational drugs —...
Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples
Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of...